Acalabrutinib study in Indian patients with chronic lymphocytic leukaemia & relapsed and refractory mantle cell lymphoma

Trial Identifier:	D8220C00022
Sponsor:	AstraZeneca
NCTID::	NCT04930536
Start Date:	July 2021
Primary Completion Date:	May 2023
Study Completion Date:	May 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
IN	Ahmedabad, IN, 380009
IN	Bangalore, IN, 560017
IN	Bangalore, IN, 560064
IN	Bengaluru, IN, 560099
IN	Chandigarh, IN, 160012
IN	Gurugram, IN, 122001
IN	Guwahati, IN, 781032
IN	Hyderabad, IN, 500019
IN	Kochi, IN, 682041
IN	Kolkata, IN, 700160
IN	Ludhiana, IN, 141 008
IN	Mumbai, IN, 400012
IN	New Delhi, IN, 110 085

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company